DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial Results

Rhea-AI Summary

DBV Technologies has announced a rescheduling of its financial results conference call for the full year 2020, now set for March 11, 2021, at 5:00 PM ET. The call will provide a financial update and a corporate overview. The event can be accessed through various teleconferencing numbers and will also be available via a live webcast on the company’s website. DBV Technologies is focused on developing Viaskin™, an innovative immunotherapy platform aimed at addressing food allergies through epicutaneous delivery methods.

Positive

• Rescheduled financial results conference call on March 11, 2021, provides clarity on performance.
• Continued focus on Viaskin™ development, which targets food allergies, indicating ongoing innovation.

Negative

• None.

Montrouge, France, March 3, 2021

DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial Results

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company has changed the date of its previously scheduled financial results conference call and live audio webcast. The Company will now report its full year 2020 financial results and provide a general corporate update on Thursday, March 11^th at 5:00pm ET (11:00pm CET).

The conference call is accessible via the below teleconferencing numbers, followed by the reference ID: 50114481.

• United States: (866) 866-1333                             
• Canada: (866) 215-5508
• United Kingdom: 0808 238 9578                       
• France: 0805 102 604

A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.

About DBV Technologies 
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com

Attachment

• PDF Version

FAQ

When is DBV Technologies' financial results call for 2020?

DBV Technologies' financial results call for 2020 is scheduled for March 11, 2021, at 5:00 PM ET.

How can I listen to DBV Technologies' conference call?

You can listen to DBV Technologies' conference call by dialing the provided teleconferencing numbers or via the live webcast available on their website.

What is Viaskin™ by DBV Technologies?

Viaskin™ is a proprietary technology platform developed by DBV Technologies that aims to provide non-invasive immunotherapy solutions for food allergies.

What ticker symbol is associated with DBV Technologies?

The ticker symbol for DBV Technologies is DBVT on the Nasdaq.